Beta Bionics Insider RSU Sale: 3,359 Shares Disposed on 09/02/2025

Rhea-AI Filing Summary

Beta Bionics, Inc. (BBNX) reporting person "Saint Sean" (identified as President & CEO and Director) executed a non-derivative sale of 3,359 common shares on 09/02/2025 at a weighted average sale price of $18.8632 per share, with the reported price range between $18.58 and $19.09. The filing states the shares were sold to cover tax withholding obligations tied to the vesting of restricted stock units. After the transaction, the reporting person is shown as beneficially owning 101,202 shares. The Form 4 was signed by an attorney-in-fact on 09/03/2025.

Positive

• Transaction disclosed promptly under Section 16 with explanation provided
• Sale was for tax withholding on RSU vesting, indicating a non-discretionary, administrative purpose
• Reporting person retains 101,202 shares, showing continued significant ownership

Negative

• Insider sale of 3,359 shares could be noted by investors as a reduction in holdings
• Form 4 signed by attorney-in-fact rather than the reporting person (documented but worth noting)

Insights

Securities Analyst

TL;DR: Insider sold a small block of shares to satisfy tax withholding from RSU vesting; ownership remains material at 101,202 shares.

The transaction is a routine, non-discretionary sale to cover tax obligations from RSU vesting rather than an open-market strategic divestiture. The reported weighted average price was $18.8632 with a range of $18.58–$19.09. Reporting person retains substantial ownership, so this transaction likely has limited immediate governance or control implications. Timely disclosure and explanation align with Section 16 reporting norms.

Corporate Governance Expert

TL;DR: Disclosure meets technical requirements; sale was mechanistic for tax withholding, not presented as a signal of management repositioning.

The Form 4 identifies the seller as both President & CEO and a director, which makes transparency important. The filing includes an explicit explanation that the sale satisfied tax withholding tied to RSU vesting and provides the weighted average price range. The signature by an attorney-in-fact is documented. No indication of change in executive roles or additional derivative activity is reported.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Saint Sean

(Last) (First) (Middle)

C/O BETA BIONICS, INC.

11 HUGHES

(Street)

IRVINE CA 92618

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Beta Bionics, Inc. [ BBNX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

3. Date of Earliest Transaction (Month/Day/Year)
09/02/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/02/2025		S(1)		3,359	D	$18.8632(2)	101,202	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

2. The weighted average sale price for the transaction reported was $18.8632 and the range of prices were between $18.58 and $19.09. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

	/s/ Stephen Feider, Attorney-in-Fact	09/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did the BBNX insider sell on 09/02/2025?

The reporting person sold 3,359 shares of Beta Bionics common stock on 09/02/2025.

Why were the BBNX shares sold according to the Form 4?

The filing states the shares were sold to cover tax withholding obligations associated with the vesting of restricted stock units.

At what price were the BBNX shares sold?

The weighted average sale price was $18.8632; reported price range was $18.58 to $19.09.

How many BBNX shares does the reporting person own after the sale?

After the transaction the reporting person is shown as beneficially owning 101,202 shares.

Who is the reporting person on the Form 4 for BBNX?

The form lists the reporting person as Saint Sean, identified as President & CEO and Director.